<SEC-DOCUMENT>0002126287-26-000001.txt : 20260413
<SEC-HEADER>0002126287-26-000001.hdr.sgml : 20260413
<ACCEPTANCE-DATETIME>20260413153333
ACCESSION NUMBER:		0002126287-26-000001
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260413
DATE AS OF CHANGE:		20260413

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Barinthus Biotherapeutics plc.
		CENTRAL INDEX KEY:			0001828185
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93002
		FILM NUMBER:		26857663

	BUSINESS ADDRESS:	
		STREET 1:		20400 CENTURY BLVD
		STREET 2:		SUITE 210
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874
		BUSINESS PHONE:		44 (0) 1865 818808

	MAIL ADDRESS:	
		STREET 1:		20400 CENTURY BLVD
		STREET 2:		SUITE 210
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech plc
		DATE OF NAME CHANGE:	20210407

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech Ltd
		DATE OF NAME CHANGE:	20201014

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			International Generosity Foundation Trust
		CENTRAL INDEX KEY:			0002126287
		ORGANIZATION NAME:           	
		EIN:				843754469
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	BUSINESS ADDRESS:	
		STREET 1:		1901 ULMERTON ROAD
		STREET 2:		SUITE 400
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33762
		BUSINESS PHONE:		7275026022

	MAIL ADDRESS:	
		STREET 1:		1901 ULMERTON ROAD
		STREET 2:		SUITE 400
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33762
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002126287</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>02/03/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001828185</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>91864C107</issuerCusipNumber>
        </issuerCusips>
        <issuerName>Barinthus Biotherapeutics plc.</issuerName>
        <address>
          <com:street1>20400 CENTURY BLVD</com:street1>
          <com:street2>SUITE 210</com:street2>
          <com:city>GERMANTOWN</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>20874</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Robert Giffen Collins</personName>
          <personPhoneNum>8138178035</personPhoneNum>
          <personAddress>
            <com:street1>1901 Ulmerton Road, Suite 400</com:street1>
            <com:city>Clearwater</com:city>
            <com:stateOrCountry>FL</com:stateOrCountry>
            <com:zipCode>33762</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002126287</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>International Generosity Foundation Trust</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>FL</citizenshipOrOrganization>
        <soleVotingPower>2734189.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2734189.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>2734189.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>6.7</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Barinthus Biotherapeutics plc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>20400 CENTURY BLVD</com:street1>
          <com:street2>SUITE 210</com:street2>
          <com:city>GERMANTOWN</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>20874</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>International Generosity Foundation Trust</filingPersonName>
        <principalBusinessAddress>1901 Ulmerton Road, Suite 400, Clearwater, Florida 33762, USA</principalBusinessAddress>
        <principalJob>The Reporting Person is a non-profit trust organized under Section 501(c) of the Internal Revenue Code. Its affairs are managed by its trustee.</principalJob>
        <hasBeenConvicted>The Reporting Person has not been convicted in any criminal proceeding during the last five years.</hasBeenConvicted>
        <convictionDescription>The Reporting Person has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws.</convictionDescription>
        <citizenship>United States of America</citizenship>
      </item2>
      <item3>
        <fundsSource>The securities reported herein were acquired by the Reporting Person through a combination of purchases and transfers.

A portion of the securities was acquired using the working capital of the Reporting Person. The Reporting Person is a non-profit trust generally funded through donations, including donor-advised funds.

The remaining securities were acquired through transfers or contributions to the Reporting Person and were not acquired through the use of funds.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Person acquired the securities for investment purposes and in connection with its charitable activities.

The Reporting Person may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes, or acquire additional securities, depending on market conditions and other factors.

Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Schedule 13D.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Aggregate Number of Shares Owned: 2,734,189
Percentage of Class of Securities Identified: 6.7</percentageOfClassSecurities>
        <numberOfShares>The Reporting Person has sole voting power with respect to 2,734,189 shares, shared voting power with respect to 0 shares, sole dispositive power with respect to 2,734,189 shares, and shared dispositive power with respect to 0 shares.</numberOfShares>
        <transactionDesc>The Reporting Person has not effected any transactions in the securities of the Issuer during the past 60 days.</transactionDesc>
        <listOfShareholders>No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.</listOfShareholders>
        <date5PercentOwnership>Not applicable</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>The Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer, other than as described in this Schedule 13D.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>None</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>International Generosity Foundation Trust</signatureReportingPerson>
        <signatureDetails>
          <signature>Robert Giffen Collins</signature>
          <title>Robert Giffen Collins</title>
          <date>04/13/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
